Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
52 patients that had previously participated in the RDBPC study of intralymphatic
immunotherapy (ILIT) with 2 concomitant allergens, birch and grass, with NCT02423707, were
eligible for an open follow up 5-6 years after treatment.